Target intelligence / Profile preview

Synaptojanin-2-binding protein (SYNJ2BP)

Target
SYNJ2BP
Molecular classification
Mitochondrial outer membrane protein, Scaffold/adaptor protein (contains PDZ domain)[4][8], Other (enzyme binding, receptor binding)[3][5]
01

Overview

Synaptojanin-2-binding protein (SYNJ2BP) is a mitochondrial outer membrane protein with a PDZ domain, acting as a scaffold/adaptor involved in multiple cellular pathways. It regulates mitochondrial morphology, supports neuronal energy supply by controlling mitochondrial transport in motor neurons, and influences mitochondrial–ER contact sites. SYNJ2BP participates in endocytosis of activin type II receptors, modulates Notch signaling by stabilizing Notch ligands, and interacts with various membrane and cytoskeletal proteins. Reduction or dysfunction of SYNJ2BP is associated with enhanced tumor growth and invasiveness in hepatocellular carcinoma and increased susceptibility to neurodegenerative diseases such as ALS. SYNJ2BP is considered both a potential therapeutic target and disease biomarker in oncology and neurology[1][2][4][5][7][8].

Other names
Synaptojanin-2-binding proteinSYNJ2BPOMP25ARIP2Mitochondrial outer membrane protein 25Activin receptor interacting protein 5
02

Mechanism of action

Not targeted by approved drugs as of current knowledge; mechanisms include modulation of receptor stability, trafficking, and signal transduction pathways such as PI3K/AKT and MAPK (in cancer and neuronal cells)[2][5]

03

Biological functions

Regulation of mitochondrial morphology and dynamics[2]Regulation of mitochondria–endoplasmic reticulum contact sites[2]Endocytosis and trafficking of activin II receptor kinases[5][3]Regulation of synaptic vesicle cycling and axonal transport in neurons[2]Stabilization of Notch ligands DLL1 and DLL4, promoting Notch signaling[1][7]Regulation of hepatocyte proliferation, metabolism, and apoptosis[2]Recruitment of certain cell adhesion molecules to mitochondria[4]
04

Disease associations

Cancer (hepatocellular carcinoma, tumor suppression/metastasis inhibition)[2]Neurodegenerative disease (motor neuron diseases, e.g., ALS)[2]Other (potential biomarker for cancer prognosis)[2]
05

Safety considerations

Therapeutic targeting could affect mitochondrial function, cellular metabolism, and cell survival, especially in neurons and liver cells. Potential risk of systemic toxicity due to its roles in fundamental cellular processes[2].
06

Biomarkers

Reduced SYNJ2BP expression may serve as a prognostic biomarker in hepatocellular carcinoma (HCC)[2]Potential marker for neuronal health or neurodegenerative progression[2]

Beyond the preview

Go deeper on Synaptojanin-2-binding protein (SYNJ2BP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptojanin-2-binding protein (SYNJ2BP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call